Summary
Disturbances of the fibrinolytic system have been associated with cardiovascular disease and its risk factors. In the present study the effects of an ACE-inhibitor (enalapril) and a placebo on the fibrinolytic system have been compared. Eighty one survivors of acute myocardial infarction were randomised to treatment with enalapril or placebo. The mass concentrations and activity of tissue plasminogen activator (tPA) and plasminogen activator inhibitor (PAI-1) in plasma were measured three months after the infarction.
The enalapril group had a significantly lower level of tPA antigen compared to the placebo-treated group (9.2 and 10.6 respectively). There was no difference between the two groups in any of the other fibrinolytic variables.
We conclude that survivors of myocardial infarction treated with enalapril have a significantly lower concentration of tPA antigen than those treated with placebo. This may have a prognostic implication, as lower plasma concentrations of tPA antigen have been associated with better prognosis in patients with established coronary heart disease.
References
Hamsten A, Walldius G, Blombäck M, de Faire U, Dahlén G, Landon C, Wiman B (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet II: 3–8
Gram J, Jespersen J, Kluft C, Rijken CD (1987) On the usefulness of fibrinolytic variables in the characterization of a risk group for myocardial infarction. Acta Med Scand 221: 149–153
Munkvald S, Gram J, Jespersen J (1990) A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction. Eur Heart J 11: 525–528
Jansson J-H, Nilsson TK, Olofsson B-O (1991) Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 12: 157–161
The CONSENSUS trial study group (1987) Effect of enalapril on mortality in severe congestive heart failure: results of the Co-operative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429–1435
The SOLVD Investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293–302
Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C (1991) A comparison of enalapril with hydralazine-isorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303–310
Schrader J, Köstering H, Gröne H-j, Kirchertz EJ, Scheler F (1982) Effects of converting enzyme inhibitor captopril on blood coagulation and fibrinolysis in man. Klin Wochenschr 60: 687–690
Ts'ao C, Gardner DV, Galluzzo TS, Molteni A (1984) Effect of captopril, MK-421 and MK-422 on fibrinolysis determined by 3 “in vitro” assays. Arch Int Pharmacodyn Ther 267: 169–176
Jansson J-H, Teger-Nilsson A-C (1991) Drug effects on the fibrinolytic system. In: Nilsson TK, Boman K, Jansson J-H (eds) Clinical Aspects of Fibrinolysis. Almqvist & Wiksell, Stockholm, pp 111–129
Grimaudo V, Hauert J, Bachman F, Kruithof EKO (1988) Diurnal variation of the fibrinolytic system. Thromb Haemost 59: 495–499
R»nby M, Sundell B, Nilsson TK (1989) Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 62: 917–922
Bergsdorf N, Nilsson T, Wallén P (1983) An enzyme-linked immunosorbent assay for tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 50: 740–744
Chmielewska J, Wiman B (1986) Determination of tissue plasminogen activator and its “fast” inhibitor from plasma. Clin Chem 32: 482–485
Paramo JA, Colucci M, Collen D, van de Werf F (1985) Plasminogen activator inhibitor in the blood of patients with coronary artery disease. Br Med J 291: 573–574
Hamsten A, Wiman B, De Faire U, Blombäck M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557–1563
Olofsson B-O, Dahlén G, Nilsson TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10: 77–82
Hellsten G, Boman K, Bjerle P, Blom P, Nilsson TK (1992) Increased plasminogen activator inhibitor and tissue plasminogen activator levels in subjects with electrocardiographic abnormality indicative of ischaemic heart disease: a cross-sectional study in Norsjö, Sweden. Eur Heart J 13: 57–60
Thorsen S, Philips M (1984) Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 802: 111–118
Nilsson TK, Olofsson BO, Jansson JH (1992) Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with angiographically verified coronary heart disease: a 7-year follow-up. (Abstract No 2383) American Heart Association, 65th Scientific Session, New Orleans. Circulation 86 [Suppl]: 1–598
Swedberg K for the CONSENSUS II Trial Study Group, Göteborg, Sweden (1991) Lack of beneficial effects on mortality by early intervention with enalapril in acute myocardial infarction. Circulation 84 [Suppl II]: 366–1457
Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins M (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction-results of the Survival and Ventricular Enlargement Trial. N Engl J Med 327: 669–677
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jansson, J.H., Boman, K. & Nilsson, T.K. Enalapril related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 44, 485–488 (1993). https://doi.org/10.1007/BF00315549
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315549